中东和非洲地尔硫卓市场预测至 2028 年 - COVID-19 影响和按产品类型(胶囊、注射剂和片剂)和应用(心绞痛、高血压等)进行的区域分析

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028


No. of Pages: 124    |    Report Code: TIPRE00025365    |    Category: Life Sciences

Middle East & Africa Diltiazem Market

市场介绍

地尔硫卓是一种苯并硫氮杂卓衍生物,具有抗高血压和血管扩张作用。地尔硫卓是一种抗高血压和血管扩张剂,通过放松血管肌肉来降低血压。这是由于降低血压具有长期治疗作用,因为它降低了致命和非致命心血管事件(如中风和心肌梗塞)的风险。根据体外结合实验,地尔硫卓与血浆蛋白的结合率为70%-80%。在临床相关浓度下,大约 40% 的药物被认为与 α-1-糖蛋白结合,而大约 30% 的药物被认为与白蛋白结合。

市场概况和动态

中东和非洲非洲地尔硫卓市场预计将从2021年的1868万美元增至2028年的3855万美元;预计 2021 年至 2028 年复合年增长率为 10.9%。政府推广举措的增加、心血管疾病 (CVD) 患病率的增加以及全球患有心脏病的老年人口的增加预计将推动该市场的发展多年来的增长。然而,地尔硫卓对消费的副作用可能会对未来几年的市场增长产生负面影响。

心脏病主要见于老年人,因为他们的免疫力较弱,其他重大健康问题。根据《2019年全球老龄化》调查,2019年全球65岁及以上人口总数为7.03亿。预计到2050年,老年人口将翻一番,达到15亿。这一人群更容易患心律失常等心血管疾病。老年人群更容易出现非典型表现、合并症和不良结果。与衰老相关的心血管系统的结构和功能变化是心血管疾病的主要原因。因此,全球老年人口的增加导致心血管疾病发病率增加,从而促进了地尔硫卓市场的增长。此外,地尔硫卓市场的特点是存在各种大小公司。市场参与者通过新产品发布、区域扩张和产品批准来增加市场份额。参与者正在投资研发以开发先进技术并在中东获得可观的收入份额。例如,2021年3月,Glenmark Pharmaceuticals的盐酸地尔硫卓缓释胶囊USP(60毫克、90毫克和120毫克)获得竞争性仿制药(CGT)称号;因此,在商业营销后,它有资格获得 180 天的 CGT 独占权。因此,近期的发展预计将成为地尔硫卓市场的未来趋势。

 

新冠疫情-19疫情的爆发已对中东和非洲地区产生了重大影响。非洲。该地区入住重症监护病房 (ICU) 的患者数量不断增加。越来越多的药物给压力重重的医疗保健系统带来了多重诊断和治疗挑战,导致医疗设备和药品的增加。此外,慢性病病例数量增加,导致抗击病毒药物的使用增加。在 COVID-19 大流行期间,人们一直担心某些降压药物的潜力,例如血管紧张素转换酶抑制剂 (ACEi) 和血管紧张素转换阻滞剂 (ARB)。目前的严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 使用膜结合的血管紧张素转换酶 2 (ACE2) 受体来促进进入宿主细胞。因此,此次疫情增强了该地区地尔硫卓市场各药品生产商的业务运营,影响相对较小。

 

主要细分市场

根据产品,中东和非洲地区非洲地尔硫卓市场分为胶囊剂、注射剂和片剂。 2021年,平板电脑细分市场占据最大市场份额。然而,胶囊细分市场预计 2021 年至 2028 年复合年增长率最快。

根据应用情况,中东和非洲地区的复合年增长率最高。非洲地尔硫卓市场分为心绞痛、高血压等。 2021年,高血压细分市场占据最大市场份额。心绞痛细分市场预计在未来几年将以最快的复合年增长率增长。

主要来源和上市公司< /strong>

与本中东和非洲地尔硫卓市场报告相关的一些主要和次要来源是迪拜卫生局 (DHA)、卫生和预防部 (MoHAP)和世界卫生组织 (WHO)。

 

 

购买报告的理由

  • 确定潜在投资基于对未来几年中东和非洲地尔硫卓市场的详细趋势分析。
  • 获得市场份额- 深入了解推动支出最高的国家/地区不同成瘾治疗药物细分市场需求的根本因素,并确定每个细分市场提供的机会。
  • 加强您对市场需求驱动因素、行业趋势和最新技术发展等方面的了解。
  • 确定推动市场增长的主要渠道 中东和非洲地尔硫卓市场,提供了未来机会的清晰图景,有助于分析,从而实现收入扩张。
  • 通过关注不同国家在中东和非洲地尔硫卓市场正在进行的项目来引导资源 span>.

 

中东和非洲地尔硫卓市场细分

按产品类型

  • 平板电脑
  • 胶囊
  • 注射剂

作者< /strong>

应用

  • 高血压
  • 心绞痛
  • 其他

按国家/地区

  • 阿联酋
  • 沙特阿拉伯
  • 南非
  • 中东和非洲其他地区

公司简介

  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN NV
  • 辉瑞公司
  • 山德士(诺华公司)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
 

Middle East & Africa Diltiazem Strategic Insights

Strategic insights for Middle East & Africa Diltiazem involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/middle-east-and-africa-diltiazem-market-strategic-framework.webp
Get more information on this report

Middle East & Africa Diltiazem Report Scope

Report Attribute Details
Market size in 2021 US$ 18.68 Million
Market Size by 2028 US$ 38.55 Million
Global CAGR (2021 - 2028) 10.9%
Historical Data 2019-2020
Forecast period 2022-2028
Segments Covered By 产品类型
  • 胶囊
  • 注射剂
  • 片剂
By 应用
  • 心绞痛
  • 高血压
Regions and Countries Covered 中东和非洲
  • 南非
  • 沙特阿拉伯
  • 阿联酋
  • 中东和非洲其他地区
Market leaders and key company profiles
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
  • Get more information on this report

    Middle East & Africa Diltiazem Regional Insights

    The regional scope of Middle East & Africa Diltiazem refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/middle-east-and-africa-diltiazem-market-geography.webp
    Get more information on this report

    The List of Companies - Middle East & Africa Diltiazem Market

    1. Bausch Health Companies Inc.
    2. Teva Pharmaceutical Industries Ltd
    3. MYLAN N.V.
    4. Pfizer Inc.
    5. Sandoz (Novartis AG)
    6. Sun Pharmaceutical Industries Ltd
    7. Hikma Pharmaceuticals PLC
    8. Zydus Cadila
    9. Glenmark
    Frequently Asked Questions
    How big is the Middle East & Africa Diltiazem Market?

    The Middle East & Africa Diltiazem Market is valued at US$ 18.68 Million in 2021, it is projected to reach US$ 38.55 Million by 2028.

    What is the CAGR for Middle East & Africa Diltiazem Market by (2021 - 2028)?

    As per our report Middle East & Africa Diltiazem Market, the market size is valued at US$ 18.68 Million in 2021, projecting it to reach US$ 38.55 Million by 2028. This translates to a CAGR of approximately 10.9% during the forecast period.

    What segments are covered in this report?

    The Middle East & Africa Diltiazem Market report typically cover these key segments-

  • 产品类型 (胶囊, 注射剂, 片剂)
  • 应用 (心绞痛, 高血压)
  • What is the historic period, base year, and forecast period taken for Middle East & Africa Diltiazem Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Middle East & Africa Diltiazem Market report:

  • Historic Period : 2019-2020
  • Base Year : 2021
  • Forecast Period : 2022-2028
  • Who are the major players in Middle East & Africa Diltiazem Market?

    The Middle East & Africa Diltiazem Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd
  • MYLAN N.V.
  • Pfizer Inc.
  • Sandoz (Novartis AG)
  • Sun Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals PLC
  • Zydus Cadila
  • Glenmark
  • Who should buy this report?

    The Middle East & Africa Diltiazem Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Middle East & Africa Diltiazem Market value chain can benefit from the information contained in a comprehensive market report.